Quarterly ResultAug 6, 2026, 05:38 PM
Iovance 2Q26 Revenue $99M, >10% Above Guidance; Cash Runway into 2H28
AI Summary
Iovance Biotherapeutics updated its corporate presentation, highlighting strong financial performance and significant pipeline progress. The company reported 2Q26 revenue of approximately $99 million, exceeding its guidance by over 10%, and achieved a 56% gross margin from cost of sales. With a cash position of $304 million, Iovance projects a cash runway into the second half of 2028. The presentation also detailed advancements in its TIL therapy pipeline, including positive clinical data for lifileucel in NSCLC and soft tissue sarcomas, and ongoing global expansion with over 95 treatment centers.
Key Highlights
- 2Q26 revenue reached ~$99M, exceeding guidance by over 10%.
- Achieved ~66% year-over-year quarterly revenue growth.
- Gross margin from cost of sales was ~56% in 2Q26 and 50% year-to-date.
- Cash, cash equivalents, and short-term investments totaled ~$304M as of June 30, 2026.
- Projects cash runway into the second half of 2028.
- Lifileucel showed 25.6% objective response rate in NSCLC with median duration of response not reached at 25.4 months follow-up.
- SARATOGA trial for soft tissue sarcomas commenced in 2Q 2026 with 50% objective response rate in early data.
- Expanded to >95 authorized treatment centers in North America.
Price Impact
More from IOVA